Condition: Diabetes Mellitus, Type 1 · Sponsor: Technical University of Munich
The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or placebo from age 6 months. The study is an investigator initiated, randomized, controlled, multicentre, multinational, primary prevention trial for children at increased risk of type 1 diabetes. The primary objective is to determine whether vaccination of children with elevated genetic risk for type 1 diabetes against COVID-19 from 6 months of age reduces the cumulative incidence of islet autoantibodies or type 1 diabetes in childhood. Secondary objectives are: 1. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of multiple islet autoantibodies in childhood. 2. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of type 1 diabetes in childhood and 3. to determine whether vaccination against COVID-19 similarly reduces the cumulative incidence of celiac disease-associated transglutaminase autoantibodies in childhood. Further exploratory objectives are described in the study protocol. Study participants will be identified through an ongoing study screening for genetic risk of type 1 diabetes using a polygenic risk score (NCT03316261). Eligible participants will be enrolled at age 3.00 to 4.00 months (baseline visit). Randomization to vaccine or placebo will occur at a…
This description comes directly from the study's public registry record.
Anette-G. Ziegler, Prof. Dr. · +49-89-3187 · anettegabriele.ziegler@helmholtz-munich.de
Peter Achenbach, Prof. Dr. · +49-89-3187 · peter.achenbach@helmholtz-munich.de
Always discuss trial participation with your own doctor first.
| Medical University of Vienna, Dept. of Pediatric and Adolescent Medicine, Waehringer Gürtel 18-20, 1090 Vienna, Austria | Vienna, Austria | Not Yet Recruiting |
| University Hospitals Leuven, Faculty of Medicine, Catholic University of Leuven | Leuven, Belgium | Recruiting |
| Klinikum rechts der Isar of Technical University Munich and Institute for Diabetes Research, Helmholtz Munich | Munich, Bavaria, Germany | Recruiting |
| AUF DER BULT, Kinder- und Jugendkrankenhaus | Hanover, Lower Saxony, Germany | Recruiting |
| Klinik und Poliklinik f. Kinder und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden | Dresden, Saxony, Germany | Recruiting |
| Lund University Dep. of Clinical Sciences Malmo, Skane University Hospital SUS | Malmö, Sweden | Recruiting |
| Birmingham Women's and Children's NHS Foundation Trust | Birmingham, United Kingdom | Not Yet Recruiting |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, United Kingdom | Not Yet Recruiting |
| The Newcastle upon Tyne Hospitals NHS Foundation Trust | Newcastle, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06452654